Cytek BioSciences Inc (NASDAQ: CTKB) on Monday, soared 5.49% from the previous trading day, before settling in for the closing price of $3.64. Within the past 52 weeks, CTKB’s price has moved between $2.37 and $7.63.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 18.28%. The company achieved an average annual earnings per share of -188.71%. With a float of $114.61 million, this company’s outstanding shares have now reached $127.60 million.
The extent of productivity of a business whose workforce counts for 648 workers is very important to gauge. In terms of profitability, gross margin is 54.94%, operating margin of -12.57%, and the pretax margin is -4.05%.
Cytek BioSciences Inc (CTKB) Insider and Institutional Ownership
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Cytek BioSciences Inc is 9.52%, while institutional ownership is 59.37%. The most recent insider transaction that took place on Jun 02 ’25, was worth 97,300. In this transaction Chief Financial Officer of this company bought 35,000 shares at a rate of $2.78, taking the stock ownership to the 55,746 shares.
Cytek BioSciences Inc (CTKB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -188.71% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Cytek BioSciences Inc (CTKB) is currently performing well based on its current performance indicators. A quick ratio of 4.95 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.47. Likewise, its price to free cash flow for the trailing twelve months is 27.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
The latest stats from [Cytek BioSciences Inc, CTKB] show that its last 5-days average volume of 1.31 million was superior to 1.0 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 83.53%.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 70.50%, which indicates a significant decrease from 97.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was lower than the 0.20 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.28, while its 200-day Moving Average is $4.65.
